MedTrace Logo

IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

NCT03562871 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2022-04-21

No results posted yet for this study

Summary

The purpose of this study is to determine if IO102 combined with pembrolizumab with or without chemotherapy is safe tolerable and effective in the treatment of Non-small Cell Lung Carcinoma (NSCLC).

The hypothesis is that IO102 will improve the objective response rate (ORR) in patients with metastatic NSCLC.

Conditions

Interventions

BIOLOGICAL

IO102

test immunotherapy

BIOLOGICAL

pembrolizumab (Keytruda)

anti-PD-1 immunotherapy

DRUG

Carboplatin (Carboplatin Kabi)

chemotherapy

DRUG

Pemetrexed (Pemetrexed Alvogen)

chemotherapy

Sponsors & Collaborators

Principal Investigators

  • James Spicer, MD Prof · Guy's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-22
Primary Completion
2021-02-06
Completion
2022-04-12
FDA Drug
Yes

Countries

  • Germany
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03562871 on ClinicalTrials.gov